ClinicalTrials.gg
Active, not recruitingNCT06060301Updated Aug 1, 2024

Topical Sulfasalazine and Oral Lichen Planus

A Phase 3 interventional study of sulfasalazine 500 MG and corticosteroids in Oral Lichen Planus, Topical Sulfasalazine and Corticosteroids, sponsored by Cairo University. Active, not recruiting at 1 site in Egypt. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Cairo University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.
  • Registered 6 months after the study started (first participant enrolled Mar 2023, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Lichen Planus, Oral by Cairo University — 1 open to participants now, 2 under way, 1 of them phase 3. Lichen Planus, Oral · Cairo University.

Enrollment
2nd of 10
46 · median 41
Started
2023
with 1 other
Phase 3
2 of 18
none open now
Registered
15th of 18
by date

Among the 18 studies in Lichen Planus, Oral by Cairo University, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 15th registered.

Lichen Planus, Oral

143 studies on the registry are indexed under Lichen Planus, Oral; 28 are open to participants now.

Browse Lichen Planus, Oral studies →

Open to participants now

1 of the 18 studies in Lichen Planus, Oral by Cairo University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 14 Lichen Planus, Oral studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Lichen Planus, Oral by Cairo University, or all of them as a file.
02

Study summary

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown.

Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.

Read the detailed description
  • Patients will be recruited in a consecutive manner from the outpatient Diagnostic center, Faculty of Dentistry, Cairo University.
  • A total number of 46 patients will be included in this study. The 23 patients categorized as study group (S group) will use topical sulfasalazine prepared by dissolving one tablet of commercially available (COLOSALAZINE - EC 500 MG 20 TAB, manufactured by: Alexandria Company for Pharmaceuticals \& Chemical Industries, Alexandria) in 100 ml of distilled water 4 times per day as a mouth wash combined with topical corticosteroids 4 times per day as a topical gel in an alternate sequence. There are no expected side effects of this treatment due to its topical application however, the patient will be instructed to stop the treatment if any adverse reactions occur such as allergy and coming to the clinic next day.
  • The 23 patients categorized as control group (C group) will receive topical corticosteroids gel only 4 times per day. The treatment regimen will be continued for 4 weeks with follow up visits one per week.
  • Medical history will be taken, thorough oral examination will be done, and a full questionnaire will be filled for each patient.
  • All participants in the study groups will undergo adequate oral hygiene performance measures with complete removal of plaque and calculus as they implement intraoral inflammation and intensify both extension and symptoms of OLP lesions. Patients will be advised to evade accidental trauma on soft tissues using soft bristles toothbrush. Acidic, spicy, hard, hot food and beverages will be avoided.
03

Conditions studied

  • Oral Lichen Planus
  • Topical Sulfasalazine
  • Corticosteroids

Browse trials for

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patients with 30-65 years old
  • Patents with atrophic OLP

Exclusion criteria

Exclusion Criteria:

    • Smokers
  • pregnant or lactating ladies and
  • Patients under topical or systemic during the last two months
  • Patients using lichenoid reaction-inducing drugs,
  • Patients with positive virus (HCV) antibodies, diabetes and hypertension
  • Patients having amalgam filling adjacent lesions will not also be included
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    study group (S group)

    The patients will use topical sulfasalazine prepared by dissolving one tablet of commercially available in 100 ml of distilled water 4 times per day as a mouth wash combined with topical corticosteroids 4 times per day as a topical gel in an alternate sequence.

    Drug: sulfasalazine 500 MG · Drug: corticosteroids

  • Active comparator
    Control group (C group)

    The 23 patients categorized as control group (C group) will receive topical corticosteroids gel only 4 times per day. The treatment regimen will be continued for 4 weeks.

    Drug: corticosteroids

Interventions

  • The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.

    Also known as: colosalazine

  • Drugcorticosteroids

    The patients will use topical corticosteroids 4 times per day.

    Also known as: kenakort in orabase

06

What researchers measure

Primary outcomes

  1. NAS

    Scale for pain assessment

    Time frame: Every week for 4 weeks period

  2. sign scoring scale of Thongprasom

    Score for severity

    Time frame: Every week for 4 weeks period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Because the research not published yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Sep 2024, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2023
First posted
Sep 29, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Oct 20, 2024
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06060301
Lead sponsor
Cairo University
Responsible party
Mai Zakaria Ibrahium Mohammed (Associate professor Oral Medicine & Periodontology, Cairo University) — Principal investigator
First posted
Sep 29, 2023
Start date
Mar 1, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Oct 20, 2024 (estimated)
Last update
Aug 1, 2024

Study contacts

Faculty O Dentistry, Cairo University
study chair · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulfasalazine

Start the discussion